2022
Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research
Kunst N, Stout N, O’Brien G, Christensen K, McMahon P, Wu A, Diller L, Yeh J. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. Journal Of The National Cancer Institute 2022, 114: 722-731. PMID: 35043946, PMCID: PMC9086756, DOI: 10.1093/jnci/djac013.Peer-Reviewed Original ResearchConceptsUsual careClinical benefitTP53 variantsIncremental cost-effectiveness ratioPathogenic TP53 variantsCancer-related deathGermline TP53 variantsUS birth cohortPotential health outcomesCost-effectiveness ratioIdentification of childrenTumor surveillanceClinical studiesRhabdomyosarcoma casesPediatric cancerEarly cancer detectionRoutine surveillanceBirth cohortHealth outcomesAge 20Newborn screeningMalignancy detectionFurther researchCareTP53
2018
Cost-effectiveness of diagnostic algorithms for peanut allergy in children
Kunst NR, Lindvik H, Carlsen KH, Håland G, Jørgensen E, Lødrup Carlsen KC. Cost-effectiveness of diagnostic algorithms for peanut allergy in children. Journal Of Allergy And Clinical Immunology 2018, 143: 1243-1246. PMID: 30445059, DOI: 10.1016/j.jaci.2018.10.050.Peer-Reviewed Original Research